Posts Tagged: Innovations and Partnerships Office (IPO)

Miroculus acquires Kapplex to advance diagnostics for complex diseases

Canadian innovation will give patients affordable, non-invasive, accurate test for cancer or infectious diseases; R&D team to remain in Toronto discovery district TORONTO and SAN FRANCISCO (May 3, 2016) — Miroculus, a San Francisco-based biotechnology company specializing in microRNA-based diagnostics, today announced an agreement to acquire Toronto-based Kapplex Inc. The Canadian company’s proprietary Digital Microfluidic (DMF) platform is built upon the research of Dr. Aaron Wheeler, a world-leader in microfluidics research at the University of Toronto. This announcement was covered in GenomeWeb and PeHub. When ... Read more

BioTuesdays features Xagenic and company’s molecular diagnostic beta trials

"Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in Europe and the U.S.," Leonard Zahr wrote in a feature article on Xagenic's product development progress for BioTuesdays on April 19, 2016. Xagenic was founded by University of Toronto Professor Shana Kelley in partnership with MaRS Innovation and U of T's Innovations & Partnerships Office in 2010. The company ... Read more

University of Toronto sperm selection technology featured in the Toronto Star

"In a project spearheaded by PhD candidate Reza Nosrati, U of T researchers are trying to learn more about the way sperm cells move — something that could benefit those using in vitro fertilization (IVF)," writes Daniel Otis in "Sperm show U of T researchers a new trick: slithering" published in the Toronto Star on November 13, 2015. MaRS Innovation is working with Professor David Sinton, Nosrati and the university's Innovations and Partnerships Office to commercialize the technology for the human sperm ... Read more

Law firm partners with UTEST program to offer legal advice to early-stage startups

TORONTO, ON (August 10, 2015) — Toronto-based law firm Aird & Berlis LLP (A&B) has become the sponsoring legal partner to the University of Toronto Early-Stage Technology Program (UTEST). This partnership was covered in TechVibes, Law Times and the Financial Post's Legal Post blog. UTEST is a 12-month incubation and acceleration program co-managed by the University of Toronto (U of T) and MaRS Innovation that allows selected U of T-affiliated early-stage startup companies to incorporate, use office space, receive mentorship and access $30,000 ... Read more

U of T researchers demonstrate new class of solar-sensitive nanoparticle

New research emerging from the University of Toronto's Edward S Rogers Sr. Department of Electrical and Computer Engineering is developing and demonstrating a new class of solar-sensitive nanoparticle. MaRS Innovation is working with Professor Ted Sargent, his research team and U of T's Innovations and Partnerships Office (IPO) to incubate and commercialize this and other solar technologies. Their work was recently published in Nature Materials. The paper's publication was widely covered in the technical trades, including CNET.com, Tech Times, Compound Semiconductor.net and ... Read more

U of T names inventors of the year, celebrates top innovators

UTEST companies and MaRS Innovation partnership recognized along with this year's honourees A better keyboard for mobile devices, intelligent traffic lights to tackle traffic jams, a more ecofriendly way to make nanoparticles for applications such as solar cells and agriculture, and an artificial neural network that improves the way computers learn. These four inventions took top honours May 21 at the University of Toronto Celebrates Innovation event. Mobile Syrup covered Whirlscape's involvement in this event. Read the story. The annual event, which has previously honoured ... Read more

QSperm: Technology to help couples get pregnant faster

MaRS Innovation and U of T's Innovations & Partnerships Office collaborating with QSperm on intellectual property and business strategy In vitro fertility treatments can be intensely emotional and medically invasive, not to mention expensive. But technical developments from a research group at the University of Toronto may soon be able to shorten the journey to pregnancy – and that potential has piqued interest from international investors. The research group, QSperm, is looking to turn their research into a biotech start-up leveraging an innovative sperm sorting design ... Read more

Whirlscape’s Minuum keyboard debuts at #2 on Google’s Top New Paid Apps list

The Minuum keyboard, which made its public debut in the Google Play Store on August 21, 2013, has already reached #2 position in Google’s “Top New Paid Android Apps” list. The keyboard is the only non-game currently in that list’s top 10. In the “Top Paid in Android Apps” general category, Minuum is already #9. The keyboard, made by Whirlscape Inc., has a four-star rating among users. (more…) Read more

Bringing mad science to mass production: Financial Post features the Bio Printer project

“It’s one thing to invent a machine that prints skin, but it’s a whole other challenge to bring what seems like the domain of mad science to mass production,” Matthew Braga wrote in  "Looking for ways to get 'skin' in the game," published in the Financial Post on July 15. The article focuses on MaRS Innovation's (MI) and the Innovations and Partnerships Office's (University of Toronto) joint efforts to commercialize the bio printer, a "prototype 3D printer that, instead of extruding layers ... Read more

Wound Healing Technology Exclusive Rights Deal with Cardium Therapeutics

TORONTO
 (October
 14,
 2010)
 –
 Of
 the
 approximately
 300
 million
 people
 around
 the
 world
 who
 are
 diabetics,
 45
 million
 of
 them
 develop 
foot
 ulcers 
that 
bleed
 – 
and 
the 
infection
 from
 those 
ulcers
 can 
spread. Working
 to
 halt
 this
 is
 Dr.
 Ping
 Lee,
 a
 professor
 at
 the
 University
 of
 Toronto’s (U of T)
 Leslie
 Dan
 Faculty
 of
 Pharmacy
 and
 GlaxoSmithKline
 chair
 in
 Pharmaceutics
 and 
Drug 
Delivery.
 He 
and 
his
 team
 have 
created 
a 
new 
sustained‐release
 form
 of
 nitric 
oxide 
(NO) 
that
 can
 not
 ... Read more